Inari Medical price target lowered to $86 from $93 at BTIG

BTIG analyst Marie Thibault lowered the firm’s price target on Inari Medical to $86 from $93 and keeps a Buy rating on the shares after its Q4 results. The company’s revenue was helped by healthy core VTE – venous thromboembolism – volumes, with traction with new products and strong outside U.S. sales, but the DoJ investigation may be an overhang, the analyst tells investors in a research note.